HCA Healthcare (HCA)
(Delayed Data from NYSE)
$397.50 USD
-5.93 (-1.47%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $397.50 0.00 (0.00%) 4:18 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$397.50 USD
-5.93 (-1.47%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $397.50 0.00 (0.00%) 4:18 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
by Zacks Equity Research
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.
Tenet Healthcare (THC) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Tenet Healthcare's (THC) Q1 results reflect strength in admissions and improved pricing yield. It expects an adjusted EPS of $8.37-$9.41 for 2024, higher than the earlier mentioned $5.76-$6.90.
Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.
Is HCA Healthcare (HCA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors Heavily Search HCA Healthcare, Inc. (HCA): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching HCA (HCA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why You Should Buy Bruker (BRKR) Stock Right Now
by Zacks Equity Research
Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
HCA Healthcare's (HCA) Q1 Earnings Beat on Rising Admissions
by Zacks Equity Research
HCA Healthcare's (HCA) quarterly results gain from broad volume-based growth along with a rising number of surgeries. Rising expenses act as a partial offset.
HCA (HCA) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HCA Healthcare (HCA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 6.99% and 2.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Why Earnings Season Could Be Great for HCA Healthcare (HCA)
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com featured highlights include Hubbel, Caterpillar, The Timken Co. and HCA Healthcare
by Zacks Equity Research
Hubbel, Caterpillar, The Timken Co. and HCA Healthcare are part of the Zacks Screen of the Week article.
Community Health Systems (CYH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 26.32% and 1.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Scoop up These 4 GARP Stocks to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. HUBB, CAT, TKR and HCA are some stocks that hold promise.
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.